Hussman Strategic Advisors Inc. Takes $519,000 Position in AxoGen, Inc. (NASDAQ:AXGN)

Hussman Strategic Advisors Inc. acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,500 shares of the medical equipment provider’s stock, valued at approximately $519,000. Hussman Strategic Advisors Inc. owned approximately 0.07% of AxoGen as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Quest Partners LLC lifted its position in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 2,076 shares during the period. R Squared Ltd purchased a new position in AxoGen during the fourth quarter worth about $30,000. Oppenheimer & Co. Inc. purchased a new position in AxoGen during the third quarter worth about $156,000. Quantbot Technologies LP purchased a new position in AxoGen during the third quarter worth about $165,000. Finally, BNP Paribas Financial Markets lifted its position in AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider’s stock worth $172,000 after buying an additional 8,656 shares during the period. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group increased their target price on AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

AxoGen Stock Performance

Shares of NASDAQ:AXGN opened at $18.51 on Friday. The firm has a market capitalization of $814.45 million, a PE ratio of -57.83 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The business has a 50-day moving average of $17.21 and a two-hundred day moving average of $14.65. AxoGen, Inc. has a 12 month low of $5.55 and a 12 month high of $19.18.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.